Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Jan;105(1):119–125. doi: 10.1111/j.1476-5381.1992.tb14221.x

The role of platelet-activating factor and peptidoleukotrienes in the vascular changes of rat passive anaphylaxis.

S Fernández-Gallardo 1, M A Gijón 1, C García 1, V Furio 1, F T Liu 1, M Sánchez Crespo 1
PMCID: PMC1908595  PMID: 1596674

Abstract

1. The role of platelet-activating factor (PAF) and peptidoleukotrienes as putative mediators of some of the vascular changes triggered by antigen was investigated in rats passively sensitized with monoclonal anti-DNP (2,4-dinitrophenyl) IgE. 2. Lethal anaphylaxis with respiratory distress, systemic hypotension, detachment of the intestinal mucosa, leukopenia and extravasation of protein-rich plasma was observed after antigen challenge of rats sensitized with partially purified monoclonal IgE at concentrations of 15 mg protein kg-1. 3. Analysis of the peritoneal fluid obtained after i.v. challenge with DNP-BSA (bovine serum albumin) showed the presence of significant amounts of PAF (101 +/- 8 pg/rat), whereas this mediator was undetectable in control animals. Leukotriene D4 was the predominant peptidoleukotriene that could be recovered after antigen challenge, and showed an extremely high concentration (92 +2- 15 ng/rat) as compared to PAF levels. 4. Extravasation of protein-rich plasma was observed shortly after challenge and reached a maximum at 30 min. Treatment of animals with i.v. PCA 4248 (1-2 mg kg-1) and WEB 2086 (1 mg kg-1), two chemically unrelated compounds which are antagonists of the PAF-receptor, produced a significant reduction of the extravasation of protein-rich plasma. 5. The same degree of protection could be afforded by MK-886, an inhibitor of leukotriene biosynthesis. Combined treatment with WEB 2086 and MK-886 provided greater inhibition of protein-rich plasma extravasation than either compound alone. PCA 4248 was also found to inhibit in a dose-dependent manner the systemic hypotension observed upon DNP-BSA challenge.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
119

Images in this article

122Figure 2
on p.122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  2. Benveniste J., Le Couedic J. P., Polonsky J., Tence M. Structural analysis of purified platelet-activating factor by lipases. Nature. 1977 Sep 8;269(5624):170–171. doi: 10.1038/269170a0. [DOI] [PubMed] [Google Scholar]
  3. Benveniste J., Tencé M., Varenne P., Bidault J., Boullet C., Polonsky J. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Seances Acad Sci D. 1979 Nov 26;289(14):1037–1040. [PubMed] [Google Scholar]
  4. Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun. 1979 Oct 29;90(4):1194–1200. doi: 10.1016/0006-291x(79)91163-x. [DOI] [PubMed] [Google Scholar]
  5. Blank M. L., Snyder F. Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. J Chromatogr. 1983 Apr 8;273(2):415–420. doi: 10.1016/s0378-4347(00)80963-9. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Capron A., Dessaint J. P., Joseph M., Rousseaux R., Capron M., Bazin H. Interaction between IgE complexes and macrophages in the rat: a new mechanism of macrophage activation. Eur J Immunol. 1977 May;7(5):315–322. doi: 10.1002/eji.1830070515. [DOI] [PubMed] [Google Scholar]
  8. Caramelo C., Fernández-Gallardo S., Marín-Cao D., Iñarrea P., Santos J. C., López-Novoa J. M., Sanchez Crespo M. Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. Biochem Biophys Res Commun. 1984 May 16;120(3):789–796. doi: 10.1016/s0006-291x(84)80176-x. [DOI] [PubMed] [Google Scholar]
  9. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  10. Chang S. W., Feddersen C. O., Henson P. M., Voelkel N. F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest. 1987 May;79(5):1498–1509. doi: 10.1172/JCI112980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clancy R. M., Hugli T. E. The extraction of leukotrienes (LTC4, LTD4, and LTE4) from tissue fluids: the metabolism of these mediators during IgE-dependent hypersensitivity reactions in lung. Anal Biochem. 1983 Aug;133(1):30–39. doi: 10.1016/0003-2697(83)90218-x. [DOI] [PubMed] [Google Scholar]
  12. Damas J. Involvement of PAF-acether in the anaphylactic shock in the rat. J Lipid Mediat. 1989 May-Jun;1(3):161–170. [PubMed] [Google Scholar]
  13. Darius H., Lefer D. J., Smith J. B., Lefer A. M. Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis. Science. 1986 Apr 4;232(4746):58–60. doi: 10.1126/science.3082008. [DOI] [PubMed] [Google Scholar]
  14. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  15. Doebber T. W., Wu M. S., Biftu T. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731. J Immunol. 1986 Jun 15;136(12):4659–4668. [PubMed] [Google Scholar]
  16. Dorrington K. J., Bennich H. Thermally induced structural changes in immunoglobulin E. J Biol Chem. 1973 Dec 25;248(24):8378–8384. [PubMed] [Google Scholar]
  17. Fernandez-Gallardo S., Cano E., Braquet P., Sanchez Crespo M. Role of paf-acether in the mediation of pathophysiological responses to aggregated immunoglobulins. Studies with the platelet-activating factor receptor antagonist BN 52021. Int J Immunopharmacol. 1988;10(4):353–360. doi: 10.1016/0192-0561(88)90121-x. [DOI] [PubMed] [Google Scholar]
  18. Fernandez-Gallardo S., Gijon M. A., Furio V., Vivanco F., Crespo M. S. Role of complement-derived peptides in thrombocytopenia elicited by soluble aggregates of immunoglobulin G in the rat. Lab Invest. 1989 May;60(5):705–713. [PubMed] [Google Scholar]
  19. Foster A., Letts G., Charleson S., Fitzsimmons B., Blacklock B., Rokach J. The in vivo production of peptide leukotrienes after pulmonary anaphylaxis in the rat. J Immunol. 1988 Nov 15;141(10):3544–3550. [PubMed] [Google Scholar]
  20. Fradin A., Zirrolli J. A., Maclouf J., Vausbinder L., Henson P. M., Murphy R. C. Platelet-activating factor and leukotriene biosynthesis in whole blood. A model for the study of transcellular arachidonate metabolism. J Immunol. 1989 Dec 1;143(11):3680–3685. [PubMed] [Google Scholar]
  21. Gonzalez-Crussi F., Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. Am J Pathol. 1983 Jul;112(1):127–135. [PMC free article] [PubMed] [Google Scholar]
  22. Guhlmann A., Keppler A., Kästner S., Krieter H., Brückner U. B., Messmer K., Keppler D. Prevention of endogenous leukotriene production during anaphylaxis in the guinea pig by an inhibitor of leukotriene biosynthesis (MK-886) but not by dexamethasone. J Exp Med. 1989 Dec 1;170(6):1905–1918. doi: 10.1084/jem.170.6.1905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hellewell P. G., Yarwood H., Williams T. J. Characteristics of oedema formation induced by N-formyl-methionyl-leucyl-phenylalanine in rabbit skin. Br J Pharmacol. 1989 May;97(1):181–189. doi: 10.1111/j.1476-5381.1989.tb11940.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Henson P. M. Activation and desensitization of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. I. Characteristics of the secretory response. J Exp Med. 1976 Apr 1;143(4):937–952. doi: 10.1084/jem.143.4.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Honda Z., Nakamura M., Miki I., Minami M., Watanabe T., Seyama Y., Okado H., Toh H., Ito K., Miyamoto T. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 1991 Jan 24;349(6307):342–346. doi: 10.1038/349342a0. [DOI] [PubMed] [Google Scholar]
  26. Hsueh W., Gonzalez-Crussi F., Arroyave J. L. Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol. 1986 Feb;122(2):231–239. [PMC free article] [PubMed] [Google Scholar]
  27. Leng W., Chang K., Williamson J. R., Jakschik B. A. Increased regional vascular albumin permeation in the rat during anaphylaxis. J Immunol. 1989 Mar 15;142(6):1982–1985. [PubMed] [Google Scholar]
  28. Leng W., Kuo C. G., Qureshi R., Jakschik B. A. Role of leukotrienes in vascular changes in the rat mesentery and skin in anaphylaxis. J Immunol. 1988 Apr 1;140(7):2361–2368. [PubMed] [Google Scholar]
  29. Liu F. T., Bohn J. W., Ferry E. L., Yamamoto H., Molinaro C. A., Sherman L. A., Klinman N. R., Katz D. H. Monoclonal dinitrophenyl-specific murine IgE antibody: preparation, isolation, and characterization. J Immunol. 1980 Jun;124(6):2728–2737. [PubMed] [Google Scholar]
  30. Lopez Diez F., Nieto M. L., Fernandez-Gallardo S., Gijon M. A., Sanchez Crespo M. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest. 1989 May;83(5):1733–1740. doi: 10.1172/JCI114074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lynch J. M., Henson P. M. The intracellular retention of newly synthesized platelet-activating factor. J Immunol. 1986 Oct 15;137(8):2653–2661. [PubMed] [Google Scholar]
  32. Martin T. R., Galli S. J., Katona I. M., Drazen J. M. Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice. J Clin Invest. 1989 Apr;83(4):1375–1383. doi: 10.1172/JCI114025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. McManus L. M., Hanahan D. J., Demopoulos C. A., Pinckard R. N. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol. 1980 Jun;124(6):2919–2924. [PubMed] [Google Scholar]
  34. Mencia-Huerta J. M., Benveniste J. Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol. 1979 May;9(5):409–415. doi: 10.1002/eji.1830090512. [DOI] [PubMed] [Google Scholar]
  35. Orange R. P., Stechschulte D. J., Austen K. F. Immunochemical and biologic properties of rat IgE. II. Capacity to mediate the immunologic releas of histamine an slow-reacting substance of anaphylaxis (SRS-A). J Immunol. 1970 Nov;105(5):1087–1095. [PubMed] [Google Scholar]
  36. Ortega M. P., García M. C., Gijón M. A., de Casa-Juana M. F., Priego J. G., Sanchez Crespo M., Sunkel C. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. J Pharmacol Exp Ther. 1990 Oct;255(1):28–33. [PubMed] [Google Scholar]
  37. Pinckard R. N., Farr R. S., Hanahan D. J. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol. 1979 Oct;123(4):1847–1857. [PubMed] [Google Scholar]
  38. Ross J. W., Smith H., Spicer B. A. Increased vascular permeability during passive peritoneal anaphylaxis in the rat. The effects of disodium cromoglycate and a nitroindanedione. Int Arch Allergy Appl Immunol. 1976;51(2):226–237. doi: 10.1159/000231595. [DOI] [PubMed] [Google Scholar]
  39. Rouzer C. A., Scott W. A., Hamill A. L., Liu F. T., Katz D. H., Cohn Z. A. Secretion of leukotriene C and other arachidonic acid metabolites by macrophages challenged with immunoglobulin E immune complexes. J Exp Med. 1982 Oct 1;156(4):1077–1086. doi: 10.1084/jem.156.4.1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. SANYAL R. K., WEST G. B. Anaphylactic shock in the albino rat. J Physiol. 1958 Aug 6;142(3):571–584. doi: 10.1113/jphysiol.1958.sp006037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smedegård G., Cui L. X., Hugli T. E. Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol. 1989 Sep;135(3):489–497. [PMC free article] [PubMed] [Google Scholar]
  42. Sok D. E., Pai J. K., Atrache V., Sih C. J. Characterization of slow reacting substances (SRSs) of rat basophilic leukemia (RBL-1) cells: effect of cysteine on SRS profile. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6481–6485. doi: 10.1073/pnas.77.11.6481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sturk A., Schaap M. C., Prins A., ten Cate J. W., van den Bosch H. Synthesis of platelet-activating factor by human blood platelets and leucocytes. Evidence against selective utilization of cellular ether-linked phospholipids. Biochim Biophys Acta. 1989 Dec 8;993(2-3):148–156. doi: 10.1016/0304-4165(89)90157-8. [DOI] [PubMed] [Google Scholar]
  44. Sun X. M., Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest. 1988 May;81(5):1328–1331. doi: 10.1172/JCI113459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sánchez-Crespo M., Alonso F., Iñarrea P., Alvarez V., Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology. 1982 Apr;4(2):173–185. doi: 10.1016/0162-3109(82)90019-4. [DOI] [PubMed] [Google Scholar]
  46. Sánchez-Crespo M., Fernández-Gallardo S., Nieto M. L., Baranès J., Braquet P. Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acether. Immunopharmacology. 1985 Oct;10(2):69–75. doi: 10.1016/0162-3109(85)90031-1. [DOI] [PubMed] [Google Scholar]
  47. Terashita Z., Imura Y., Shino A., Nishikawa K. A lethal role of platelet activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther. 1987 Oct;243(1):378–383. [PubMed] [Google Scholar]
  48. Tomioka K., Garrido R., Ahmed A., Stevenson J. S., Abraham W. M. YM461, a PAF antagonist, blocks antigen-induced late airway responses and airway hyperresponsiveness in allergic sheep. Eur J Pharmacol. 1989 Nov 7;170(3):209–215. doi: 10.1016/0014-2999(89)90541-4. [DOI] [PubMed] [Google Scholar]
  49. Triggiani M., Hubbard W. C., Chilton F. H. Synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol. 1990 Jun 15;144(12):4773–4780. [PubMed] [Google Scholar]
  50. Wei Y. F., Heghinian K., Bell R. L., Jakschik B. A. Contribution of macrophages to immediate hypersensitivity reaction. J Immunol. 1986 Sep 15;137(6):1993–2000. [PubMed] [Google Scholar]
  51. del Balzo U., Polley M. J., Levi R. Cardiac anaphylaxis. Complement activation as an amplification system. Circ Res. 1989 Sep;65(3):847–857. doi: 10.1161/01.res.65.3.847. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES